Kurt R Brunden

List of Publications by Year
in descending order

51 papers	3,947 citations	159358 30 h-index	205818 48 g-index
51 all docs	51 docs citations	51 times ranked	5261 citing authors

#	Article	IF	Citations
1	Alzheimerâ€™s Disease Drug Discovery in Academia: From High-Throughput Screening to In Vivo Testing. , 2022, , 34-44.		0
2	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. Acta Neuropathologica, 2022, 143, 15-31.	3.9	29
3	Congeners Derived from Microtubule-Active Phenylpyrimidines Produce a Potent and Long-Lasting Paralysis of Schistosoma mansoni In Vitro. ACS Infectious Diseases, 2021, 7, 1089-1103.	1.8	6
4	In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics. Acta Neuropathologica, 2021, 141, 193-215.	3.9	30
5	Evaluation of the Structureâ€“Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5-a]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies. Journal of Medicinal Chemistry, 2021, 64, 1073-1102.	2.9	17
6	Effects of microglial depletion and TREM2 deficiency on AÎ² plaque burden and neuritic plaque tau pathology in 5XFAD mice. Acta Neuropathologica Communications, 2021, 9, 150.	2.4	19
7	Characterization of novel conformation-selective Î±-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. Neurobiology of Disease, 2020, 136, 104712.	2.1	31
8	Characterization of tau binding by gosuranemab. Neurobiology of Disease, 2020, 146, 105120.	2.1	36
9	Correction of microtubule defects within AÎ² plaqueâ€associated dystrophic axons results in lowered AÎ² release and plaque deposition. Alzheimer's and Dementia, 2020, 16, 1345-1357.	0.4	11
10	Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2020, 15, 64.	4.4	19
11	Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays. Journal of Biological Chemistry, 2020, 295, 4001-4013.	1.6	10
12	1,2,4-Triazolo[1,5-a]pyrimidines in drug design. European Journal of Medicinal Chemistry, 2019, 165, 332-346.	2.6	68
13	Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2180-2183.	1.0	21
14	A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model. Molecular Neurodegeneration, 2018, 13, 59.	4.4	27
15	Amyloid-Î² plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nature Medicine, 2018, 24, 29-38.	15.2	433
16	Brainâ€Penetrant Triazolopyrimidine and Phenylpyrimidine Microtubule Stabilizers as Potential Leads to Treat Human African Trypanosomiasis. ChemMedChem, 2018, 13, 1751-1754.	1.6	19
17	Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimerâ€™s and Other Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2017, 60, 5120-5145.	2.9	40
18	Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. Neurobiology of Disease, 2017, 105, 328-335.	2.1	74

#	Article	IF	Citations
19	Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies. ACS Chemical Neuroscience, 2017, 8, 5-7.	1.7	20
20	Evaluation of Oxetan-3-ol, Thietan-3-ol, and Derivatives Thereof as Bioisosteres of the Carboxylic Acid Functional Group. ACS Medicinal Chemistry Letters, 2017, 8, 864-868.	1.3	32
21	Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors. Scientific Reports, 2016, 5, 18286.	1.6	37
22	Microtubule-Stabilizing Agents for Alzheimerâ€™s and Other Tauopathies. Topics in Medicinal Chemistry, 2016, , 159-179.	0.4	5
23	The Dynamics and Turnover of Tau Aggregates in Cultured Cells. Journal of Biological Chemistry, 2016, 291, 13175-13193.	1.6	59
24	Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimer's and Dementia, 2016, 12, 1051-1065.	0.4	91
25	Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy. Acta Neuropathologica Communications, 2016, 4, 106.	2.4	45
26	Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimers Disease and Related Tauopathies. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 432-450.	1.3	58
27	Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4980-4982.	1.0	31
28	Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiology of Disease, 2015, 73, 83-95.	2.1	168
29	Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models. PLoS ONE, 2015, 10, e0125614.	1.1	124
30	Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimerâ€™s Disease and Related Tauopathies. Journal of Medicinal Chemistry, 2014, 57, 6116-6127.	2.9	84
31	Potent, Long-Acting Cyclopentane-1,3-Dione Thromboxane (A₂)-Receptor Antagonists. ACS Medicinal Chemistry Letters, 2014, 5, 1015-1020.	1.3	6
32	Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. Bioorganic and Medicinal Chemistry, 2014, 22, 5040-5049.	1.4	87
33	O3-12-05: INTRACEREBRAL INJECTION OF PREFORMED SYNTHETIC TAU FIBRILS INITIATES WIDESPREAD TAUOPATHY AND NEURONAL LOSS IN THE BRAINS OF TAU TRANSGENIC MICE. , 2014, 10, P234-P234.		0
34	MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. ACS Medicinal Chemistry Letters, 2013, 4, 886-889.	1.3	33
35	Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation. Journal of Biological Chemistry, 2013, 288, 11024-11037.	1.6	128
36	Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochemical Society Transactions, 2012, 40, 661-666.	1.6	39

#	Article	IF	Citations
37	Brain-Penetrant Tetrahydronaphthalene Thromboxane A2-Prostanoid (TP) Receptor Antagonists as Prototype Therapeutics for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2012, 3, 928-940.	1.7	22
38	A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research. , 2012, 8, 564-573.		16
39	Microtubule Stabilizing Agents as Potential Treatment for Alzheimerâ€™s Disease and Related Neurodegenerative Tauopathies. Journal of Medicinal Chemistry, 2012, 55, 8979-8996.	2.9	151
40	Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structureâ€“activity relationship leads to selection of candidates with desirable in vivo properties. Bioorganic and Medicinal Chemistry, 2012, 20, 4451-4461.	1.4	29
41	The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice. Journal of Neuroscience, 2012, 32, 3601-3611.	1.7	325
42	The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. Pharmacological Research, 2011, 63, 341-351.	3.1	135
43	Chronic Stress Exacerbates Tau Pathology, Neurodegeneration, and Cognitive Performance through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism in a Transgenic Mouse Model of Tauopathy. Journal of Neuroscience, 2011, 31, 14436-14449.	1.7	201
44	Developing Therapeutic Approaches to Tau, Selected Kinases, and Related Neuronal Protein Targets. Cold Spring Harbor Perspectives in Medicine, 2011, 1, a006437-a006437.	2.9	101
45	Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy. Journal of Neuroscience, 2010, 30, 13861-13866.	1.7	256
46	Discovery of Brain-Penetrant, Orally Bioavailable Aminothienopyridazine Inhibitors of Tau Aggregation. Journal of Medicinal Chemistry, 2010, 53, 3739-3747.	2.9	47
47	Tau-directed drug discovery for Alzheimer's disease and related tauopathies: A focus on tau assembly inhibitors. Experimental Neurology, 2010, 223, 304-310.	2.0	81
48	Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nature Reviews Drug Discovery, 2009, 8, 783-793.	21.5	383
49	Identification of Aminothienopyridazine Inhibitors of Tau Assembly by Quantitative High-Throughput Screening. Biochemistry, 2009, 48, 7732-7745.	1.2	101
50	Evidence that Non-Fibrillar Tau Causes Pathology Linked to Neurodegeneration and Behavioral Impairments. Journal of Alzheimer's Disease, 2008, 14, 393-399.	1.2	106
51	Identification of Novel and Improved Antimitotic Agents Derived from Noscapine. Journal of Medicinal Chemistry, 2005, 48, 7096-7098.	2.9	56